إسرائيل - العربية - Ministry of Health

pfizer pharmaceuticals israel ltd - azithromycin as dihydrate 200 mg / 5 ml - powder for suspension - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

إسرائيل - العربية - Ministry of Health

dexcel ltd - ofloxacin 200 mg - caplets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as: upper and lower urinary tract infections, lower respiratory tract infections uncomplicated urethral and cervical gonorrhoea, non-gonococcal urethritis and cervicitis, skin and soft tissue infections.

إسرائيل - العربية - Ministry of Health

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

إسرائيل - العربية - Ministry of Health

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po